Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

American Society of Clinical Oncology (ASCO) - Tập 28 Số 11 - Trang 1963-1972 - 2010
Patrick Y. Wen1, David R. Macdonald1, David A. Reardon1, Timothy F. Cloughesy1, A. Gregory Sorensen1, Evanthia Galanis1, John DeGroot1, Wolfgang Wick1, Mark R. Gilbert1, Andrew B. Lassman1, Christina Tsien1, Tom Mikkelsen1, Eric T. Wong1, Marc C. Chamberlain1, Roger Stupp1, Kathleen R. Lamborn1, Michael A. Vogelbaum1, Martin J. van den Bent1, Susan M. Chang1
1From the Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center; Division of Neurology, Brigham and Women's Hospital; Department of Radiology, Massachusetts General Hospital; Brain Tumor Center, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC; Neuro-Oncology Program, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; Division of Neuro...

Tóm tắt

Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra0708126

10.1200/JCO.1999.17.8.2572

10.1215/15228517-2007-062

10.1200/JCO.1990.8.7.1277

WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No. 48 1979 WHO Geneva, Switzerland WHO

10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

10.1097/00019052-200312000-00001

10.1093/jnci/92.3.205

10.1016/j.ejca.2008.10.026

10.1093/jnci/93.18.1401

10.1215/S1522851705000529

10.1215/15228517-2005-005

10.1200/JCO.2001.19.2.551

10.1038/ncponc1204

10.3174/ajnr.A0963

10.1200/JCO.2009.22.4998

10.1212/WNL.38.5.724

10.1200/JCO.1994.12.9.1886

10.3171/jns.1996.84.2.0174

10.1148/radiology.217.2.r00nv36377

10.1212/01.wnl.0000242894.21705.3c

10.1016/j.surneu.2006.04.015

10.1056/NEJMoa043330

10.6004/jnccn.2008.0037

10.1212/01.WNL.0000133398.11870.9A

10.1016/S1470-2045(08)70125-6

10.1007/s11060-006-9241-y

10.1002/cncr.23562

10.1200/JCO.2007.14.8163

10.1002/ana.410170607

10.1148/radiology.204.3.9280269

10.1017/S0317167100046643

10.3171/jns.2005.103.3.0428

Matheus MG, 2004, Am J Neuroradiol, 25, 1211

10.3171/jns.2005.102.2.0267

Floeth FW, 2001, Am J Neuroradiol, 22, 1517

10.1023/A:1014571900854

10.1016/j.ncl.2007.07.010

10.2967/jnumed.106.037689

10.1016/j.crad.2008.07.002

10.1016/j.crad.2006.09.012

10.1016/j.ccr.2006.11.021

10.1200/JCO.2007.12.2440

10.1200/JCO.2008.19.8721

10.1200/JCO.2008.16.3055

10.1007/s11060-008-9745-8

10.1158/0008-5472.CAN-09-0814

10.1212/01.wnl.0000304121.57857.38

10.1200/jco.2008.26.15_suppl.13000

10.1016/S1474-4422(08)70260-6

10.1038/sj.neo.7900102

10.1016/j.ccr.2009.01.027

10.1038/nrc2442

10.1007/978-0-387-75587-8_1

10.1055/s-0028-1083696

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 28 Số 11

1963-1972

Thông tin tác giả